{"url_path":"/sec/flgt/8-k/2026-05-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1674930/0001674930-26-000025-index.html","accession_number":"0001674930-26-000025","cik":"0001674930","ticker":"FLGT","issuer_name":"Fulgent Genetics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1674930/0001674930-26-000025-index.html","primary_entity_key":"0001674930","primary_entity_name":"Fulgent Genetics, Inc."},"word_count":78,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn May 21, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company's full abstract entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”, presenting interim data from the Company's open-label, randomized Phase 2 study, was released. A copy of the Company’s press release containing this information is filed as Exhibit 99.1 to this Current Report on Form 8-K."}